Skip to main content
. 2020 Jun 19;177(1):281–299. doi: 10.1093/toxsci/kfaa088

Figure 5.

Figure 5.

Summary of bioactivation liver response assay (BA-LRA) signature scores and association with drug-induced liver injury (DILI) risk. A, The relationship of BA-LRA score and maximum daily clinical dose for the combined 116 compound DILI training and test set. Maximum daily clinical doses, rat study doses and study durations, and resulting BA-LRA scores are listed in Supplementary Table 1. Data for compounds deemed insufficiently tested are not plotted. Green circles indicate compounds with a lack of evidence for liver injury in humans, whereas red x’s indicate compounds with the ability to cause liver injury in humans. Dashed green line indicates BA-LRA burden (BA-LRA score × maximum daily clinical dose) threshold of 0.85. B, The BA-LRA burden (BA-LRA score × maximum daily clinical dose based) is plotted for the same compounds in (A). Compounds with a lack of (−) or ability (+) to cause liver injury in humans are plotted in green and red, respectively. Dashed green line indicates a BA-LRA burden threshold of 0.85. C, Matrix (2 × 2) of the association of DILI risk and BA-LRA burden > 0.85. Red highlights number of true positives, green the number of true negatives. Abbreviations: Sens, sensitivity; Spec, specificity.